Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 26

Sort by

Sort Order Select

Journal Articles

Clonal Dynamics of Gene Mutations during Oral Azacitidine Maintenance Therapy in Patients with Acute Myeloid Leukemia (AML): Outcomes from the QUAZAR AML-001 Trial

Daniel Lopes De Menezes, Manuel Ugidos Guerrero, Arnaud Amzallag, Wendy L. See, Alberto Risueno, Charalampos Kyriakopoulos, Rajasekhar N.V.S. Suragani, Barry S. Skikne, C.L. Beach, Thomas Prebet, Maria Teresa Voso, Andre C. Schuh, Gail J. Roboz, Hartmut Döhner, Andrew H. Wei, Anita K. Gandhi

Blood (2023) 142 (Supplement 1): 1582.

https://doi.org/10.1182/blood-2023-187651

Published: 2023

Journal Articles

Prognostic impact of NPM1 and FLT3 mutations in patients with AML in first remission treated with oral azacitidine

Hartmut Döhner, Andrew H. Wei, Gail J. Roboz, Pau Montesinos, Felicitas R. Thol, Farhad Ravandi, Hervé Dombret, Kimmo Porkka, Irwindeep Sandhu, Barry Skikne, Wendy L. See, Manuel Ugidos, Alberto Risueño, Esther T. Chan, Anjan Thakurta, C.L. Beach, Daniel Lopes de Menezes

Blood (2022) 140 (15): 1674–1685.

https://doi.org/10.1182/blood.2022016293

Published: 2022

Includes: Supplemental data

Journal Articles

Long-Term Overall Survival (OS) with Oral Azacitidine (Oral-AZA) in Patients with Acute Myeloid Leukemia (AML) in First Remission after Intensive Chemotherapy (IC): Updated Results from the Phase 3 QUAZAR AML-001 Trial

Andrew H. Wei, Hartmut Döhner, Hamid Sayar, Farhad Ravandi, Pau Montesinos, Hervé Dombret, Dominik Selleslag, Kimmo Porkka, Jun Ho Jang, Barry Skikne, C.L. Beach, Yu (Olivia) Tian, Gail J. Roboz

Blood (2021) 138 (Supplement 1): 871.

https://doi.org/10.1182/blood-2021-147501

Published: 2021

Journal Articles

Phase 1/2 Study Investigating CC-90011, a Potent, Selective, and Reversible Oral Inhibitor of Lysine-Specific Demethylase 1 (LSD1), Plus Concurrent Venetoclax (VEN) and Azacitidine (AZA) in Patients with Acute Myeloid Leukemia (AML)

Courtney D. DiNardo, Gautam Borthakur, Brian Ball, Harry P. Erba, Raya Mawad, Marina Kremyanskaya, James S. Blachly, Hetty E. Carraway, Ahrim Youn, Jessica Garzon, Daniel Lopes de Menezes, Patricia Martin-Regueira, C.L. Beach, Justin Watts

Blood (2021) 138 (Supplement 1): 4430.

https://doi.org/10.1182/blood-2021-146791

Published: 2021

Journal Articles

Matching Adjusted Indirect Comparison (MAIC) of Oral Azacitidine (Oral-AZA) Versus Injectable AZA in Patients (pts) with Acute Myeloid Leukemia (AML) in First Remission after Intensive Induction Chemotherapy

Clara Chen, Gerwin A. Huls, Heather Cameron, Beatrice Suero, Alberto Vasconcelos, Lona Gaugler, C.L. Beach

Blood (2021) 138 (Supplement 1): 3015.

https://doi.org/10.1182/blood-2021-148049

Published: 2021

Journal Articles

Prognostic Impact of NPM1 and FLT3 Mutations at Diagnosis and Presence of Measurable Residual Disease (MRD) after Intensive Chemotherapy (IC) for Patients with Acute Myeloid Leukemia (AML) in Remission: Outcomes from the QUAZAR AML-001 Trial of Oral Azacitidine (Oral-AZA) Maintenance

Hartmut Döhner, Andrew H. Wei, Gail J. Roboz, Pau Montesinos, Felicitas R Thol, Farhad Ravandi, Hervé Dombret, Kimmo Porkka, Irwindeep Sandhu, Barry Skikne, Wendy L. See, Manuel Ugidos, Alberto Risueño, Esther Chan, Anjan Thakurta, C.L. Beach, Daniel Lopes de Menezes

Blood (2021) 138 (Supplement 1): 804.

https://doi.org/10.1182/blood-2021-147465

Published: 2021

Journal Articles

CC-486 Mechanism Imparted By Extended Exposure of Azacitidine Upregulates Myeloid Differentiation Markers and Induces Cell Death in AML Cells

Diana R. Dunshee, Yumin Dai, Jessica C. Jang, Alberto Risueño, Danny V Jeyaraju, Patrick Hagner, PhD, Wendy L. See, Kyle MacBeth, Xiaomin Wang, Ignazia La Torre, Barry Skikne, MD, C.L. Beach, PharmD, Keshava Kumar, PhD, Anjan Thakurta, Daniel Lopes de Menezes, PhD

Blood (2020) 136 (Supplement 1): 33–34.

https://doi.org/10.1182/blood-2020-137606

Published: 2020

Journal Articles

Gastrointestinal Events and Management Strategies for Patients with Acute Myeloid Leukemia (AML) in First Remission Receiving CC-486 in the Randomized, Placebo-Controlled, Phase III QUAZAR AML-001 Maintenance Trial

Farhad Ravandi, MBBS, Christopher Pocock, MBBS, Dominik Selleslag, MD, Pau Montesinos, MD PhD, Hamid Sayar, MD MSc, Maurizio Musso, MD, Angela Figuera Alvarez, Hana Safah, MD, William Tse, MD FACP, Sang Kyun Sohn, MDPhD, Devendra K Hiwase, MBBS, MD FRACP, FRCPA, PhD, Timothy Chevassut, Francesca Pierdomenico, Ignazia La Torre, Barry Skikne, MD, Keshava Kumar, PhD, Qian Dong, DrPH, C.L. Beach, PharmD, Hervé Dombret, MD

Blood (2020) 136 (Supplement 1): 22–23.

https://doi.org/10.1182/blood-2020-137669

Published: 2020

Journal Articles

CC-486 Improves Overall Survival (OS) and Relapse-Free Survival (RFS) for Patients with Acute Myeloid Leukemia (AML) in First Remission after Intensive Chemotherapy (IC), Regardless of Amount of Consolidation Received: Results from the Phase III QUAZAR AML-001 Maintenance Trial

Andrew Wei, MBBS,PhD, Gail J. Roboz, MD, Hervé Dombret, MD, Hartmut Döhner, Andre C. Schuh, Pau Montesinos, MD PhD, Christopher Pocock, MBBS, Dominik Selleslag, MD, Sergey N. Bondarenko, Ignazia La Torre, Barry Skikne, MD, Keshava Kumar, PhD, Qian Dong, DrPH, C.L. Beach, PharmD, Farhad Ravandi, MBBS

Blood (2020) 136 (Supplement 1): 38–40.

https://doi.org/10.1182/blood-2020-138498

Published: 2020

Journal Articles

CC-486 Reduces Hospitalization and Associated Estimated Costs in Patients with Acute Myeloid Leukemia (AML) in First Remission after Intensive Chemotherapy: Results from the QUAZAR AML-001 Maintenance Trial

Esther Natalie Oliva, MD, Suman Kambhampati, MD, Albert Oriol, Ignazia La Torre, Barry Skikne, MD, C.L. Beach, PharmD, Keshava Kumar, PhD, Qian Dong, DrPH, Clara Chen, Sandip Ranjan, MTech, Zephirin Kiendrebeogo, Msc, PMP, Thorsten Braun, MD PhD

Blood (2020) 136 (Supplement 1): 14–15.

https://doi.org/10.1182/blood-2020-137562

Published: 2020

Journal Articles

CC-486 Prolongs Survival for Patients with Acute Myeloid Leukemia (AML) in Remission after Intensive Chemotherapy (IC) Independent of the Presence of Measurable Residual Disease (MRD) at Study Entry: Results from the QUAZAR AML-001 Maintenance Trial

Gail J. Roboz, MD, Farhad Ravandi, MBBS, Andrew H Wei, MBBS, PhD, Hervé Dombret, MD, Hartmut Döhner, Felicitas Thol, Maria Teresa Voso, MD, Andre C. Schuh, Kimmo Porkka, Ignazia La Torre, Barry Skikne, MD, Keshava Kumar, PhD, Qian Dong, DrPH, C.L. Beach, PharmD, Alberto Risueño, Daniel Lopes de Menezes, PhD, Gert Ossenkoppele, MD PhD

Blood (2020) 136 (Supplement 1): 32–33.

https://doi.org/10.1182/blood-2020-140837

Published: 2020

Journal Articles

Impact of Gene Mutations on Overall Survival in Older Patients with Acute Myeloid Leukemia (AML) Treated with Azacitidine (AZA) or Conventional Care Regimens (CCR)

Lin Tang, PhD, Anna Dolnik, PhD, Kyle J. MacBeth, PhD, Hervé Dombret, Prof., John F. Seymour, MD, Mark D. Minden, MD PhD, Richard M. Stone, MD, C.L. Beach, PharmD, Hartmut Döhner, MD, Lars Bullinger, MD

Blood (2016) 128 (22): 2859.

https://doi.org/10.1182/blood.V128.22.2859.2859

Published: 2016

Journal Articles

Efficacy and Safety of Azacitidine (AZA) Versus Conventional Care Regimens (CCR) in Patients Aged ≥75 Years with Acute Myeloid Leukemia (AML) in the Phase 3 AZA-AML-001 Study

John F. Seymour, MD, Rena Buckstein, MD, Valeria Santini, MD, Hartmut Döhner, MD, Richard M. Stone, MD, Mark D. Minden, MD PhD, Ching-Yuan Kuo, MD, Dina Ben-Yehuda, MD, Joan Bargay, MD, Stephen Songer, PharmD, Jerry Weaver, PhD, C.L. Beach, PharmD, Hervé Dombret, Prof.

Blood (2016) 128 (22): 2818.

https://doi.org/10.1182/blood.V128.22.2818.2818

Published: 2016

Journal Articles

Azacitidine (AZA) Prolongs Overall Survival in Older Patients with Acute Myeloid Leukemia (AML) with Poor Prognostic Karyotypes Compared with Conventional Care Regimens (CCR)

Hartmut Döhner, MD, Paresh Vyas, MD PhD, John F. Seymour, MD, Valeria Santini, MD, Richard M. Stone, MD, Mark D. Minden, MD PhD, Haifa Kathrin Al-Ali, MD, Teresa Bernal del Castillo, MD PhD, John Morrill, MS, Stephen Songer, PharmD, Jerry Weaver, PhD, Barry S. Skikne, MD, C.L. Beach, PharmD, Hervé Dombret, Prof.

Blood (2016) 128 (22): 1638.

https://doi.org/10.1182/blood.V128.22.1638.1638

Published: 2016

Journal Articles

Impact of Somatic Gene Mutations on Response to Lenalidomide (LEN) in IPSS Lower-Risk Myelodysplastic Syndromes (MDS) Patients (Pts) without Del(5q) and Ineligible for or Refractory to Erythropoiesis-Stimulating Agents (ESAs)

Valeria Santini, MD, Pierre Fenaux, MD PhD, Aristoteles Giagounidis, Uwe Platzbecker, MD, Alan F List, MD, Jianhua Zhong, PhD, Chengqing Wu, PhD, Konstantinos Mavrommatis, C.L. Beach, PharmD, Albert Hoenekopp, MD, Kyle J. MacBeth, PhD

Blood (2016) 128 (22): 225.

https://doi.org/10.1182/blood.V128.22.225.225

Published: 2016

Journal Articles

The Safety and Tolerability of Azacitidine (AZA) Are Comparable in Patients with Acute Myeloid Leukemia (AML) or Higher-Risk Myelodysplastic Syndromes (MDS)

John F. Seymour, MBBS, PhD, Lewis R. Silverman, MD, Hartmut Döhner, Prof. MD, Pierre Fenaux, MD PhD, Ghulam J. Mufti, MD PhD, Valeria Santini, MD, Mark D. Minden, MD PhD, Richard M. Stone, MD, Lela M. Lucy, PhD, Stephen Songer, PharmD, Donna Dougherty, BSN, Randy Hinkle, RPh, MBA, Dominique Gambini, MD, C.L. Beach, PharmD, Hervé Dombret

Blood (2015) 126 (23): 3754.

https://doi.org/10.1182/blood.V126.23.3754.3754

Published: 2015

Journal Articles

Efficacy and Safety of Lenalidomide (LEN) Versus Placebo (PBO) in RBC-Transfusion Dependent (TD) Patients (Pts) with IPSS Low/Intermediate (Int-1)-Risk Myelodysplastic Syndromes (MDS) without Del(5q) and Unresponsive or Refractory to Erythropoiesis-Stimulating Agents (ESAs): Results from a Randomized Phase 3 Study (CC-5013-MDS-005)

Blood (2014) 124 (21): 409.

https://doi.org/10.1182/blood.V124.21.409.409

Published: 2014

Journal Articles

Quality of Life and Productivity Impact of Myelodysplastic Syndromes (MDS): The Patient Perspective

Dalia Mahmoud, MBA, Stacie Hudgens, MS, Fiona Taylor, MBiochem, Farrah Pompilus, MA, Steve Hwang, BA, C.L. Beach, PharmD

Blood (2012) 120 (21): 4705.

https://doi.org/10.1182/blood.V120.21.4705.4705

Published: 2012

Journal Articles

Bone Marrow Hypocellularity Does Not Impair the Tolerability or Efficacy of Azacitidine (AZA) in Patients with Higher-Risk Myelodysplastic Syndromes Treated in the AZA-001 Study

John F Seymour, MB, BS, PhD, FRACP, John M. Bennett, MD, Alan F List, MD, Ghulam J. Mufti, MD, Steven D. Gore, MD, Pierre Fenaux, MD, PhD, Valeria Santini, MD, Joel Hetzer, PhD, Stephen Songer, PharmD, Barry S. Skikne, MD, C.L. Beach, PharmD

Blood (2012) 120 (21): 3808.

https://doi.org/10.1182/blood.V120.21.3808.3808

Published: 2012

Journal Articles

A 10 Day Schedule of Azacitidine Induces More Complete Cytogenetic Remissions Than the Standard Schedule In Myelodysplasia and Acute Myeloid Leukemia with Myelodysplasia-Related Changes: Results of the E1905 US Leukemia Intergroup Study

Thomas Prebet, M.D., Ph.D., Zhuoxin Sun, PhD, Rhett Ketterling, Gary Hicks, Ph.D., C.L. Beach, PharmD, Peter L. Greenberg, MD, Elisabeth Paietta, PhD, Magdalena Czader, M.D., Ph.D., Janice Gabrilove, M.D., Harry P Erba, DM, PhD, Martin S. Tallman, MD, Steven D. Gore, M.D.

Blood (2010) 116 (21): 4013.

https://doi.org/10.1182/blood.V116.21.4013.4013

Published: 2010

NARROW

Clonal Dynamics of Gene Mutations during Oral Azacitidine Maintenance Therapy in Patients with Acute Myeloid Leukemia (AML): Outcomes from the QUAZAR AML-001 Trial

Prognostic impact of NPM1 and FLT3 mutations in patients with AML in first remission treated with oral azacitidine

Long-Term Overall Survival (OS) with Oral Azacitidine (Oral-AZA) in Patients with Acute Myeloid Leukemia (AML) in First Remission after Intensive Chemotherapy (IC): Updated Results from the Phase 3 QUAZAR AML-001 Trial

Phase 1/2 Study Investigating CC-90011, a Potent, Selective, and Reversible Oral Inhibitor of Lysine-Specific Demethylase 1 (LSD1), Plus Concurrent Venetoclax (VEN) and Azacitidine (AZA) in Patients with Acute Myeloid Leukemia (AML)

Matching Adjusted Indirect Comparison (MAIC) of Oral Azacitidine (Oral-AZA) Versus Injectable AZA in Patients (pts) with Acute Myeloid Leukemia (AML) in First Remission after Intensive Induction Chemotherapy

Prognostic Impact of NPM1 and FLT3 Mutations at Diagnosis and Presence of Measurable Residual Disease (MRD) after Intensive Chemotherapy (IC) for Patients with Acute Myeloid Leukemia (AML) in Remission: Outcomes from the QUAZAR AML-001 Trial of Oral Azacitidine (Oral-AZA) Maintenance

CC-486 Mechanism Imparted By Extended Exposure of Azacitidine Upregulates Myeloid Differentiation Markers and Induces Cell Death in AML Cells

Gastrointestinal Events and Management Strategies for Patients with Acute Myeloid Leukemia (AML) in First Remission Receiving CC-486 in the Randomized, Placebo-Controlled, Phase III QUAZAR AML-001 Maintenance Trial

CC-486 Improves Overall Survival (OS) and Relapse-Free Survival (RFS) for Patients with Acute Myeloid Leukemia (AML) in First Remission after Intensive Chemotherapy (IC), Regardless of Amount of Consolidation Received: Results from the Phase III QUAZAR AML-001 Maintenance Trial

CC-486 Reduces Hospitalization and Associated Estimated Costs in Patients with Acute Myeloid Leukemia (AML) in First Remission after Intensive Chemotherapy: Results from the QUAZAR AML-001 Maintenance Trial

CC-486 Prolongs Survival for Patients with Acute Myeloid Leukemia (AML) in Remission after Intensive Chemotherapy (IC) Independent of the Presence of Measurable Residual Disease (MRD) at Study Entry: Results from the QUAZAR AML-001 Maintenance Trial

Impact of Gene Mutations on Overall Survival in Older Patients with Acute Myeloid Leukemia (AML) Treated with Azacitidine (AZA) or Conventional Care Regimens (CCR)

Efficacy and Safety of Azacitidine (AZA) Versus Conventional Care Regimens (CCR) in Patients Aged ≥75 Years with Acute Myeloid Leukemia (AML) in the Phase 3 AZA-AML-001 Study

Azacitidine (AZA) Prolongs Overall Survival in Older Patients with Acute Myeloid Leukemia (AML) with Poor Prognostic Karyotypes Compared with Conventional Care Regimens (CCR)

Impact of Somatic Gene Mutations on Response to Lenalidomide (LEN) in IPSS Lower-Risk Myelodysplastic Syndromes (MDS) Patients (Pts) without Del(5q) and Ineligible for or Refractory to Erythropoiesis-Stimulating Agents (ESAs)

The Safety and Tolerability of Azacitidine (AZA) Are Comparable in Patients with Acute Myeloid Leukemia (AML) or Higher-Risk Myelodysplastic Syndromes (MDS)

Quality of Life and Productivity Impact of Myelodysplastic Syndromes (MDS): The Patient Perspective

Bone Marrow Hypocellularity Does Not Impair the Tolerability or Efficacy of Azacitidine (AZA) in Patients with Higher-Risk Myelodysplastic Syndromes Treated in the AZA-001 Study

A 10 Day Schedule of Azacitidine Induces More Complete Cytogenetic Remissions Than the Standard Schedule In Myelodysplasia and Acute Myeloid Leukemia with Myelodysplasia-Related Changes: Results of the E1905 US Leukemia Intergroup Study

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only